Customize your JAMA Network experience by selecting one or more topics from the list below.
Cerebrotendinous xanthomatosis (CTX) is a rare but treatable neurodegenerative disorder caused by 27-sterol hydroxylase (CYP27) deficiency.
To describe clinical features and results of genetic analysis in a family with CTX.
A 54-year-old woman with CTX, her family members, and 115 white control subjects.
Main Outcome Measures
Results of clinical evaluation and magnetic resonance imaging of the brain in the affected subject; results of mutation analysis of the CYP27 coding sequence in the patient, her parents, and the control subjects.
The proband and her affected sibling had classic features of CTX, including presenile cataracts, tendon xanthomas, diarrhea, and a complex neurodegenerative disorder. They were somewhat atypical, however, because their cataracts were congenital, cognitive impairment had been noted in childhood, and the white matter involvement was more severe than usual. The proband was shown to be homozygous for CYP27 mutation R362C. Similar analysis of 115 control subjects identified 1 subject who was a heterozygous carrier for this same CYP27 mutation.
The prevalence of CTX due to CYP27 mutation R362C alone is approximately 1 per 50 000 among white individuals. Although the disorder is rare, this incidence is substantially greater than previously recognized. Greater awareness of CTX is important because specific treatment is available.
Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous Xanthomatosis: Possible Higher Prevalence Than Previously Recognized. Arch Neurol. 2005;62(9):1459–1463. doi:10.1001/archneur.62.9.1459
Create a personal account or sign in to: